Shares of Moderna Inc (BMV:MRNA) (NASDAQ:MRNA) climbed 5.4% mid-day Tuesday as remarks by RFK Jr, who clarified his stance as not being anti-vaccine or anti-industry, appeared to bolster investor ...

Another company that scored an approval for its mRNA COVID-19 vaccine, Moderna, is also progressing its pipeline of candidates against cancer. The bulk of its targets within cancer utilise its ...

On one of the final days of the Biden Administration, the US Department of Health and Human Services (HHS) announced $590 million in support for Moderna to speed the development of mRNA vaccines ...

Moderna's new version of its COVID-19 vaccine, which targets two virus variants including Omicron, has outperformed the company's original Spikevax shot in a head-to-head clinical trial.

Moderna's MRNA +3.99% Get Free Report short percent of float has risen 13.6% since its last report. The company recently ...

Moderna (MRNA) closed the latest trading day at $41.66, indicating a +0.6% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily loss of 1.46%. Elsewhere ...